STOCKS TELEGRAPH

Tag: NASD:MYGN

  • Myriad Genetics (MYGN) Stock Soars After Hours On Strong Earnings

    Myriad Genetics (MYGN) Stock Soars After Hours On Strong Earnings

    During the extended session on Tuesday, Myriad Genetics, Inc. (NASDAQ: MYGN) had a significant 38.24% increase in its stock price, reaching $5.35. Following the announcement of its impressive second-quarter results, which demonstrated great operational performance, positive market trends, and strategic development objectives, there was a sudden spike in after-hours trading.

    Robust Q2 Performance Driven by Cancer Testing Strength

    Myriad Genetics reported $213.1 million in sales for the second quarter of 2025, a 1% increase from the previous year. Stronger average revenue per test, greater laboratory efficiency, and product mix optimization all contributed to the gross margin’s improvement to 71.2%, up more than 160 basis points from the previous year.

    Growth was sustained by the company’s oncology hereditary cancer diagnostics as well as rising adoption among unaffected people.

    Prioritizing the Cancer Care Continuum Strategically

    Three main pillars have been the focus of Myriad Genetics’ thorough examination of its long-term growth plan. First and foremost, the firm intends to increase its position in the Cancer Care Continuum (CCC) by expanding its testing offering to encompass Molecular Residual Disease (MRD) diagnostics, immuno-oncology therapy monitoring, and therapy selection.

    The proprietary MRD test is expected to enter early access launch in the first half of 2026. Investments in research, development, commercial capabilities, and customer digital experience are being prioritized to better capture CCC opportunities.

    Financing and Operational Discipline to Support Growth

    To enhance financial flexibility, Myriad Genetics entered into a new $200 million credit facility on July 31, 2025. Additionally, it secured non-dilutive financing from OrbiMed to bolster long-term initiatives.

    The company also aims to grow Prenatal Health revenue through recently launched tests, including the Prequel NIPS test, and plans the commercial debut of the FirstGene Multiple Prenatal Screen in 2026. In Mental Health, emphasis will be placed on high-value GeneSight accounts and leveraging favorable biomarker legislation.

    Myriad Genetics projects high single-digit to low double-digit revenue growth over the next five years, complemented by margin expansion through cost discipline, operational efficiency, and stable pricing strategies.

  • Myriad Genetics (MYGN) Rides High: Exploring The Surging Stock Momentum

    Myriad Genetics (MYGN) Rides High: Exploring The Surging Stock Momentum

    In the wake of a robust financial report, Myriad Genetics, Inc. (NASDAQ: MYGN) is currently experiencing an upward trajectory in its stock performance on the US stock market. As of the last check during current-market session, MYGN shares have surged by 18.30%, reaching $23.40.

    Strong Financial Performance In Q1 2024

    Myriad Genetics (MYGN) commenced 2024 with notable momentum, marked by substantial double-digit revenue growth compared to the previous year, a marked improvement in year-over-year net losses, and the attainment of positive adjusted EBITDA in the initial quarter.

    Expansion In Market Share And Revenue Per Test

    During the first quarter, Myriad Genetics witnessed promising signs of securing market share in hereditary cancer and prenatal testing, with expectations of this trend gaining momentum as the year progresses. Additionally, the average revenue per test across its product spectrum in the first quarter benefited from expanded coverage and the company’s persistent efforts in revenue cycle management.

    Ongoing Product Development And Enhancements

    Myriad Genetics remains sanguine about the evolution of its product range, as it continues to undertake additional clinical validation studies and edges closer to the launch of novel products. Simultaneously, the company is actively pursuing enhancements to facilitate access and usability, including integrations with electronic medical records (EMR), and is making significant headway in its Labs of the Future initiative.

    Research Collaborations And Integration Efforts

    On the corporate front, Myriad Genetics has forged a research collaboration with the National Cancer Center Hospital East in Japan to delve into the prognostic and predictive potential of MRD testing utilizing Myriad Genetics’ highly sensitive test, Precise MRD. Furthermore, it has progressed in integrating the recently acquired CLIA-certified laboratory and Precise Tumor and Liquid assays from Intermountain Precision Genomics.

    Corporate Restructuring And Strategic Divestitures

    In addition, Myriad Genetics has announced the restructuring of its European operations and the divestiture of its EndoPredict business to Eurobio Scientific. Nonetheless, the company retains the licensing rights to produce and distribute EndoPredict in the U.S., aiming to realign its resources towards domestic opportunities while maintaining services for key biopharma partners and patients beyond the U.S. Additionally, Myriad will grant Eurobio the right to market Prolaris in vitro diagnostic kits outside the U.S.